LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Aglepristone and cloprostenol combination in the termination of late-term pregnancy in queens

    Karakas Alkan, Kubra / Alkan, Hasan / Tez, Gizem / Kanca, Halit

    Journal of feline medicine and surgery. 2020 Oct., v. 22, no. 10

    2020  

    Abstract: Termination rates for the highly recommended aglepristone (AGL) treatment are low in late-term pregnancy in queens. We studied the effects of an AGL and cloprostenol (CLO) combination in the termination of late-term pregnancy. Pregnant queens were ... ...

    Abstract Termination rates for the highly recommended aglepristone (AGL) treatment are low in late-term pregnancy in queens. We studied the effects of an AGL and cloprostenol (CLO) combination in the termination of late-term pregnancy. Pregnant queens were assigned to two groups. Queens in the AGL group (n = 10) received AGL 10 mg/kg, twice, 24 h apart. Queens in the AGL-CLO group (n = 9) were additionally injected with a single dose of CLO (5 μg/kg) 24 h after the second dose of AGL. Progesterone, 17beta(β)-oestradiol, cortisol, oxytocin and prostaglandin F2alpha (PGF2α) metabolite were measured in sera obtained at days 0, 1 and 2, and on the day of abortion. Average gestational age in both groups was similar (AGL 38.61 ± 0.91 days vs AGL-CLO 39.39 ± 1.35 days; P >0.05). Termination rates were 80% and 100% in the AGL and AGL-CLO groups, respectively (P <0.05). Fetal expulsion time was significantly longer (P <0.001) in the AGL group (96.9 ± 6 h) compared with the AGL-CLO group (69.8 ± 3.3 h). Duration of abortion was 19.8 ± 2.6 h and 12.6 ± 1.4 h in the AGL and AGL-CLO groups, respectively (P <0.05). Both treatments were well tolerated. Significantly (P <0.05) lower serum progesterone concentrations were observed in both groups at the day of abortion and concentrations in the AGL-CLO group (4.19 ± 0.80 ng/ml) were lower than in the AGL group (9.89 ± 2.21 ng/ml; P <0.05). AGL and CLO combination increases pregnancy termination rate in late-term pregnant queens. In addition, CLO contributes to a decrease in luteal function in AGL-treated late-term pregnant queens.
    Keywords blood serum ; cats ; cloprostenol ; cortisol ; dosage ; duration ; gestational age ; medicine ; metabolites ; oxytocin ; pregnancy ; progesterone ; surgery
    Language English
    Dates of publication 2020-10
    Size p. 907-915.
    Publishing place SAGE Publications
    Document type Article
    Note NAL-light
    ZDB-ID 2049047-1
    ISSN 1532-2750 ; 1098-612X
    ISSN (online) 1532-2750
    ISSN 1098-612X
    DOI 10.1177/1098612X19892087
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Aglepristone and cloprostenol combination in the termination of late-term pregnancy in queens.

    Karakas Alkan, Kubra / Alkan, Hasan / Tez, Gizem / Kanca, Halit

    Journal of feline medicine and surgery

    2019  Volume 22, Issue 10, Page(s) 907–915

    Abstract: Objectives: Termination rates for the highly recommended aglepristone (AGL) treatment are low in late-term pregnancy in queens. We studied the effects of an AGL and cloprostenol (CLO) combination in the termination of late-term pregnancy.: Methods: ... ...

    Abstract Objectives: Termination rates for the highly recommended aglepristone (AGL) treatment are low in late-term pregnancy in queens. We studied the effects of an AGL and cloprostenol (CLO) combination in the termination of late-term pregnancy.
    Methods: Pregnant queens were assigned to two groups. Queens in the AGL group (n = 10) received AGL 10 mg/kg, twice, 24 h apart. Queens in the AGL-CLO group (n = 9) were additionally injected with a single dose of CLO (5 μg/kg) 24 h after the second dose of AGL. Progesterone, 17beta(β)-oestradiol, cortisol, oxytocin and prostaglandin F2alpha (PGF2α) metabolite were measured in sera obtained at days 0, 1 and 2, and on the day of abortion.
    Results: Average gestational age in both groups was similar (AGL 38.61 ± 0.91 days vs AGL-CLO 39.39 ± 1.35 days;
    Conclusions and relevance: AGL and CLO combination increases pregnancy termination rate in late-term pregnant queens. In addition, CLO contributes to a decrease in luteal function in AGL-treated late-term pregnant queens.
    MeSH term(s) Abortifacient Agents/administration & dosage ; Abortion, Induced/methods ; Abortion, Induced/veterinary ; Animals ; Cats ; Cloprostenol/administration & dosage ; Drug Combinations ; Estrenes/administration & dosage ; Female
    Chemical Substances Abortifacient Agents ; Drug Combinations ; Estrenes ; aglepristone (0UT4JLE1CM) ; Cloprostenol (4208238832)
    Language English
    Publishing date 2019-12-13
    Publishing country England
    Document type Clinical Trial, Veterinary ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2049047-1
    ISSN 1532-2750 ; 1098-612X
    ISSN (online) 1532-2750
    ISSN 1098-612X
    DOI 10.1177/1098612X19892087
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour.

    Kanca, Halit / Tez, Gizem / Bal, Kazim / Ozen, Dogukan / Alcigir, Eray / Atalay Vural, Sevil

    Veterinary medicine and science

    2018  Volume 4, Issue 4, Page(s) 364–372

    Abstract: Canine transmissible venereal tumour (CTVT) is a naturally occurring contagious neoplasm of dogs located mainly on the external genitalia of both sexes. The course of vincristine chemotherapy, the most effective and practical therapy, is affected by the ... ...

    Abstract Canine transmissible venereal tumour (CTVT) is a naturally occurring contagious neoplasm of dogs located mainly on the external genitalia of both sexes. The course of vincristine chemotherapy, the most effective and practical therapy, is affected by the immune status of the host. The aim was to investigate recombinant human interferon alpha-2a (rhIFNα-2a) and vincristine for treatment of CTVT. A total of 21 female dogs were included. In group I (n = 9), vincristine (0.025 mg/kg, IV) was administered weekly. In group II (n = 6), dogs were injected intratumorally weekly with 1.5 million IU rhIFNα-2a. In group III (n = 6), rhIFNα-2a and vincristine were combined. No tumour regression was observed after three injections of rhIFNα-2a in group II and weekly vincristine was administered. The number of tumour infiltrating lymphocytes (TILs), mitotic figures and apoptotic cells were counted in subsequent incisional tumour biopsies. The Kaplan-Meier Method was used to analyse survival using complete tumour regression as the outcome and Breslow Test was used for comparison of survival curves. Differences in TILs, cell proliferation and apoptosis between groups were assessed by analysis of covariance. Complete regression was observed in all animals included. Mean duration of vincristine treatment for complete regression was shorter in group II (3.50 weeks, 95% CI, 3.06-3.94, P < 0.05) and group III (3.17 weeks, 95% CI, 2.84-3.49, P < 0.01) compared to group I (5.11 weeks, 95% CI, 4.42-5.80). Vincristine and rhIFNα-2a combination increased TILs in CTVT biopsies compared to vincristine treatment (P = 0.017) and vincristine treatment after rhIFNα-2a (P = 0.049). Vincristine treatment after rhIFNα-2a (Group II; P < 0.001) and rhIFNα-2a and vincristine combination (Group III; P < 0.001) decreased apoptosis. The results indicate that intratumoral rhIFNα-2a treatment alone is not effective in CTVT. However, combination of rhIFNα-2a and vincristine shortens the duration of treatment compared to vincristine therapy.
    MeSH term(s) Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Dog Diseases/drug therapy ; Dogs ; Drug Therapy, Combination ; Female ; Interferon alpha-2/administration & dosage ; Interferon alpha-2/therapeutic use ; Venereal Tumors, Veterinary/drug therapy ; Vincristine/administration & dosage ; Vincristine/therapeutic use
    Chemical Substances Antineoplastic Agents ; Interferon alpha-2 ; Vincristine (5J49Q6B70F)
    Language English
    Publishing date 2018-08-17
    Publishing country England
    Document type Clinical Trial, Veterinary ; Journal Article
    ZDB-ID 2819409-3
    ISSN 2053-1095 ; 2053-1095
    ISSN (online) 2053-1095
    ISSN 2053-1095
    DOI 10.1002/vms3.119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top